Comparison of enoxaparin and unfractionated heparin in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

摘要: Background: No randomized trial has been conducted to directly compare enoxaparin with unfractionated heparin (UFH) in patients undergoing percutaneous coronary intervention (PCI) for non-ST-segment elevation acute syndrome (NSTE-ACS). In an era where early invasive strategies are recommended high risk patients, the effect of and UFH needs be re-evaluated. The authors performed a meta-analysis determine whether is superior NSTE-ACS PCI. Methods: composite efficacy end point included all-cause mortality myocardial infarction (MI) hospital or within 60 days. Major bleeding, as defined individual clinical trials evaluated, was main safety endpoint same time period. Pooled estimates difference outcome between were calculated using fixed random effects models. Results: A total 8,861 from 4 included. pooled analysis, rates death MI similar treated [risk ratio (RR), 0.89, 95% confidence interval (CI): 0.77–1.02, P=0.09; I 2 =50%]. bleeding also (RR, 1.21, CI: 0.94–1.56, P=0.15, =39%). subgroup including only large sample size, leave-one-out sensitivity demonstrated results above, respectively. Conclusions: PCI NSTE-ACS, both death/MI major UFH.